Rare disease division will be decimated

Discussion in 'Shire' started by Anonymous, Jul 15, 2014 at 12:24 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Two separate sales forces selling 2 different drugs in the same rare disease market. Abbvie will see that as low hanging fruit in cost cutting after the buyout. I dreaded this as the way this division was handled after we bought ViroPharma was rediculous.

    Start looking for jobs BEFORE you need to!
     

  2. Anonymous

    Anonymous Guest

    There are companies due to come out soon with drugs in this space. Do a little research and you'll find them.
     
  3. Anonymous

    Anonymous Guest

    If you are so smart you should have seen this happening like the rest of us already did. Just stick around for the money until we get cut loose. We'll have no problems finding jobs.
     
  4. Anonymous

    Anonymous Guest

    Both drugs appear to be selling pretty well, and with only 50-60 reps in total selling both drugs there really isn't much savings that would come from combining into a single field force. I think Shire knows what they are doing. Guess we'll see if AbbVie does too.
     
  5. Anonymous

    Anonymous Guest

    There are def savings by combining the two. Less sr mgmt needed, same systems, less ops people to manage diff systems and processes, etc.... OneShire! We are sooooo bad at integrations
     
  6. Anonymous

    Anonymous Guest

    New recombinant competitor just got approved. They are hiring a new sales force!
     
  7. Anonymous

    Anonymous Guest

    WRONG! Perry is now going to run division!!!!!!
     
  8. Anonymous

    Anonymous Guest

    Please, take him and his vp of sales too
     
  9. Anonymous

    Anonymous Guest

    Or go to Salix with the rest of us